All In Biotech

Drug Trial Radar · NCT07893093

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Two Formulations of ASC36 Injection in Participants With Obesity or Overweight

A Phase I, Randomized, Placebo-controlled, Double-blind, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Two Formulations of ASC36 Injection for Subcutaneous Use in Adult Participants With Obesity or Are Overweight

Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 144 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

144

Planned (sponsor's estimate)

Start

Sep 28, 2026

Primary completion

Jun 2027

Study completion Jun 2027

Sponsor

Sponsor type
Industry
First posted
Oct 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized, double-blind, placebo-controlled single ascending dose (SAD)/ multiple ascending dose (MAD) study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of Two Formulations of ASC36 injection

Conditions

  • Chronic Weight Management

Interventions

  • ASC36 Injection A, for subcutaneous useDrug

    ASC36 Injection A is an investigational formulation of ASC36 administered by subcutaneous injection.

  • ASC36 Placebo Injection A, for subcutaneous useDrug

    ASC36 Placebo Injection A is an placebo injection matching ASC36 Injection A.

  • ASC36 Injection B, for subcutaneous useDrug

    ASC36 Injection B is an investigational formulation of ASC36 administered by subcutaneous injection.

  • ASC36 Placebo Injection B, for subcutaneous useDrug

    ASC36 Placebo Injection B is an placebo injection matching ASC36 Injection B.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse EventsTime frame: From baseline to the end of treatment (up to 16 weeks or Day 113)
  2. Adverse EventsTime frame: From baseline to the end of treatment (up to 20 weeks or Day 141)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Ascletis Clinical Site

    San Antonio, Texas · Recruiting

  • Ascletis Clinical Site

    Salt Lake City, Utah · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.